Diabetes Drug Jardiance Drives Boehringer Ingelheim Revenue

The diabetes medication Jardiance has significantly boosted Boehringer Ingelheim's revenue, contributing 5.7 billion euros to the German pharmaceutical company's total sales of 15.8 billion euros.

Post Share

Sources

Showing 0 of 1 sources

No articles available in your preferred languages.

1 article available in other languages below.

die-presseGerman47d ago

Diabetesmittel treibt Umsatz von Boehringer Ingelheim in die Höhe

Noch ist Jardiance in Europa nicht zugelassen, aber dafür in anderen Märkten und brachte dem deutschen Pharmakonzern allein 5,7 Milliarden Euro. Insgesamt stieg der Umsatz auf 15,8 Milliarden Euro.

Read full article →

Diabetes Drug Jardiance Drives Boehringer Ingelheim Revenue

Sources

Diabetesmittel treibt Umsatz von Boehringer Ingelheim in die Höhe

Related Stories

Lionel Richie Hospitalized in ICU Following St. Louis Concert

Anna Hazare admitted to Mumbai hospital's ICU with acute dehydration, kidney issue

Ebola Outbreak in Democratic Republic of Congo Surpasses 6,000 Cases

England Pharmacies to Offer Free Quick Cholesterol Screening Tests